Pricing

How can companies adapt their single evidence package at launch into multiple, tailored versions for HTAs that vary across different countries and regions?

David Bower and Agata Wiśniowska discuss how addressing payer needs in the product development process can help companies increase patient access to their novel treatments.

The introduction of alternative payment models and specialty pharmacy benefit management (SPBM) is poised to usher in a new era of affordability for expensive gene therapies.

With Sen. Bernie Sanders leading the charge on Capitol Hill, the campaign to limit U.S. outlays for prescription drugs has accelerated.

We all make mistakes — and that includes those involved in Health Technology Assessment (HTA). Following an error made by ICER this year, Leela Barham looks at similar mistakes made in the past and what can be done about them.

How can pharmaceutical companies successfully apply advanced analytics? Pricing experts from Simon-Kucher & Partners identify the hurdles and winning approaches.

Post-Brexit, the UK’s MHRA is looking to join Project Orbis, a global program to speed up patient access to innovative cancer treatments. This article looks at the implications of Project Orbis for commercialization in the UK and the key considerations for industry in considering the project as a pathway.

With Democrats controlling Congress and the White House, expectations are high that policy makers will revise certain coverage and payment policies. Jill Wechsler reports.

How biopharma manufacturers can address extreme pricing of novel rare disease medicines and build legitimacy into commercialization to avoid an industrywide crisis.

Outlining the steps to a payment approach for Medicare Part D drugs that provides savings for patients.

Amid COVID-19, pressure for “socially responsible” pricing could temper investments in future urgent healthcare needs.

How technology can maximize use of manufacturer copay and patient assistance programs.

Rasim Shah talks about how the application of AI to Pricing and Reimbursement can dramatically free up time spent on crunching datasets, modeling scenarios, and building price predictions.

The second of two articles summarizing the broad range of government efforts to control drug pricing focuses on state government efforts.

Ira Studin takes a look at how pharma manufacturers can address extreme pricing and build legitimacy into commercialization to avoid an industry-wide crisis.

Efforts to address prescription drug pricing have expanded. Rick Kelly reports.

Even advocates of U.S. drug pricing reform recognize that President Trump's revised initiative to reduce the price of prescription drugs is unlikely to save money for consumers or the government.

President Trump has taken on the pharma industry in a surprise move making significant cuts in reimbursement for drugs covered by Medicare.

Tasked with setting up framework for essential medicine program.

COVID-19 has only magnified well known flaws of our healthcare system. An extension of Medicare is the affordable solution, writes Bruno Delagneau, and pharma needs to start planning for this to minimize its impact on US revenues.

A look into the complex battle between pharmaceutical manufacturers and payers for balance between medication access and budget management.

Should therapies and vaccines be cheap or free in a pandemic and would that really dry up innovation?

White House initiative to encourage U.S. production of essential medicines calls on FDA to set program parameters for implement main aspects.

Should therapies and vaccines be cheap or free in a pandemic and would that really dry up innovation?

Bill Barr outlines the systematic application of three criteria to guide discounting decisions.

The rapid pace of new pharmaceutical approvals raises questions of whether ICER can keep up and maintain the quality and rigor demanded by healthcare audiences, writes Jeremy Schafer.

ISPOR has published its third issue of the top trends in HEOR. Leela Barham takes a look at how the list has changed over time.

In a a new report penned by CEOs, more than 200 biopharma leaders acknowledge that out-of-pocket costs for individuals must be limited to sustain support for fiscal and patent policies key to advancing innovation.

A look at two surveys that reveal payer perspectives regarding current and future management of high-cost durable therapies with one-time administration.

This article discusses how cost differences with other countries reflect income differences, how these differences are typical for cost in medical services, and more.